Skye Bioscience, Inc.
Other OTC•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Punit S. Dhillon B.A.
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11250 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Nov 26, 2014
- CIK
- 0001516551
- Website
- skyebioscience.com
- Similar Companies
- Business
- Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Company News
Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Skye Bioscience to Present at TD Cowen Health Care Conference
Skye Bioscience Announces Participation in February Conferences
MoneyShow's Best Investment Ideas For 2025: Part 8
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Skye Bioscience to Announce Third Quarter 2024 Results
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
Skye: Moving Weight Loss Drugs To The Next Level
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings